Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Interact Cardiovasc Thorac Surg ; 28(3): 410-412, 2019 03 01.
Article in English | MEDLINE | ID: mdl-30295799

ABSTRACT

IgG4-related disease (IgG4-RD) is a progressive inflammatory disease that might rarely involve only the lungs. We retrospectively reviewed the preoperative, clinical and surgical features of patients with a pathology highly suggestive or probable diagnosis of IgG4-RD without extra-thoracic involvement. Five patients were selected, 2 were operated on the right side. Positron emission tomography-computed tomography (PET-CT) showed an uptake in all the patients (median 5.5), and 2 patients had an uptake at the thoracic lymph nodes. Two diagnoses were made through a CT-guided needle biopsy, while 3 were determined based on a lung wedge resection. The levels of serum IgG4 were elevated (>1.35 g/dl) in all the patients. Two patients had a highly suggestive diagnosis of IgG4-RD, and 3 patients had a probable diagnosis of IgG4-RD. The differential diagnosis between IgG4-RD and lung malignancies based only on radiological features is challenging and often requires histological confirmation. A careful preoperative workup and a multidisciplinary approach to PET-positive nodules might help to avoid unnecessary major lung resections.


Subject(s)
Immunoglobulin G4-Related Disease/diagnosis , Lung Neoplasms/diagnosis , Lung/diagnostic imaging , Positron Emission Tomography Computed Tomography/methods , Aged , Aged, 80 and over , Biopsy , Diagnosis, Differential , Female , Humans , Male , Retrospective Studies
2.
J Thorac Oncol ; 13(8): 1113-1120, 2018 08.
Article in English | MEDLINE | ID: mdl-29704674

ABSTRACT

INTRODUCTION: Determination of programmed death ligand 1 (PD-L1) expression defines eligibility for treatment with pembrolizumab in patients with advanced NSCLC. This study was designed to better define which value across core biopsy specimens from the same case more closely reflects the PD-L1 expression status on whole sections and how many core biopsy specimens are needed for confident classification of tumors in terms of PD-L1 expression. METHODS: We built tissue microarrays as surrogates of biopsies collecting five cores per case from 268 cases and compared PD-L1 staining results obtained by using the validated clone SP263 with the results obtained by using whole tumor sections. RESULTS: We found an overall positivity in 39% of cases at a cutoff of 1% and in 10% of cases at a cutoff of 50%. The maximum value across cores was associated with high concordance between cores and whole sections and the lowest number of false-negative cases overall. To reach high concordance with whole sections, four and three cores are necessary at cutoffs of 1% and 50%, respectively. Importantly, with 20% as the cutoff for core biopsy specimens, fewer than three cores showed high sensitivity and specificity in identifying cases with 50% or more of tumor cells positive for PD-L1 on whole sections. Specifically, for PD-L1 expression values of 20% to 49% on cores, the probabilities of a tumor specimen expressing PD-L1 in at least 50% of cells on a whole section were 46% and 24% with one and two biopsy specimens, respectively. CONCLUSIONS: An accurate definition of the criteria to determine the PD-L1 status of a given tumor may greatly help in selecting those patients who could benefit from anti-programmed cell death 1/PD-L1 treatment.


Subject(s)
B7-H1 Antigen/biosynthesis , Biomarkers, Tumor/metabolism , Carcinoma, Non-Small-Cell Lung/metabolism , Lung Neoplasms/metabolism , Adult , Aged , Aged, 80 and over , B7-H1 Antigen/immunology , Biopsy/methods , Carcinoma, Non-Small-Cell Lung/immunology , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Non-Small-Cell Lung/surgery , Female , Humans , Immunohistochemistry , Lung Neoplasms/immunology , Lung Neoplasms/pathology , Lung Neoplasms/surgery , Male , Microtomy , Middle Aged , Tissue Array Analysis
3.
Am J Trop Med Hyg ; 97(6): 1808-1809, 2017 Dec.
Article in English | MEDLINE | ID: mdl-29016305

ABSTRACT

Schistosomiasis causes mainly hepatic and genitourinary damage. Although lung nodules have been commonly described in acute phase, they are presumably underdiagnosed in chronic schistosomiasis. We previously reported a series of patients with chronic pulmonary schistosomiasis confirmed by the histological examination of the lung biopsies. In the present work, we retrospectively tested an in-house real-time polymerase chain reaction for Schistosoma (currently validated for diagnosis on stool and on urine) in the bronchoalveolar lavage (BAL) of a couple of those patients, and both resulted positive. The possibility of testing BAL with molecular methods targeting a wide spectrum of pathogens, including parasites, is appealing. Further studies are needed to validate this technique that might reduce unnecessary biopsies.


Subject(s)
Bronchoalveolar Lavage , Lung Diseases, Parasitic/diagnosis , Real-Time Polymerase Chain Reaction , Schistosomiasis/diagnosis , Adult , Animals , Bronchoalveolar Lavage Fluid/parasitology , Cote d'Ivoire , Feces/parasitology , Humans , Lung Diseases, Parasitic/urine , Mali , Reproducibility of Results , Retrospective Studies , Schistosoma/isolation & purification , Schistosoma haematobium/isolation & purification , Schistosoma mansoni/isolation & purification , Schistosomiasis/urine
4.
Thorac Surg Clin ; 27(1): 47-55, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27865327

ABSTRACT

Malignant pleural effusion (MPE) symptoms have a real impact on quality of life. Surgical approach through video-assisted thoracic surgery provides a first step in palliation. In patients unfit for general anesthesia, awake pleuroscopy represents an alternative. Sclerosing agents can be administered at the bedside through a chest tube. Ideal treatment of MPE should include adequate long-term symptom relief, minimize hospitalization, and reduce adverse effects. Indwelling pleural catheter (IPC) allows outpatient management of MPE through periodic ambulatory fluid drainage. IPC offers advantages over pleurodesis in patients with poor functional status who cannot tolerate pleurodesis or in patients with trapped lungs.


Subject(s)
Catheters, Indwelling , Chest Tubes , Drainage/methods , Pleural Effusion, Malignant/surgery , Humans , Lung Neoplasms/complications , Pleural Effusion, Malignant/etiology , Pleurodesis , Quality of Life , Thoracic Surgery, Video-Assisted
5.
Ann Transl Med ; 4(16): 304, 2016 Aug.
Article in English | MEDLINE | ID: mdl-27668224

ABSTRACT

BACKGROUND: Pepsin plays a role in gastroesophageal reflux (GER). Aims of this study were to verify if pepsin could be the cause of frequent bronchial exacerbations and to check if the persistence of chronic respiratory symptoms were correlated with pre-existing respiratory diseases. METHODS: From January to May 2016, 42 patients underwent a diagnostic bronchoscopy. All patients had a history of at least one bronchial exacerbation during the previous year. Bronchial lavage fluid specimens were obtained. A semiquantitative assessment of pepsin in the samples was carried out based on the intensity of the test sample. RESULTS: Pepsin was present in 37 patients (88%), but in patients with bronchial asthma and chronic obstructive pulmonary disease (COPD), the finding of pepsin in the bronchoalveolar fluid was 100%. There was a strong positive statistical correlation between pepsin detection and radiological signs of GER (ρ=0.662), and between pepsin detection and diagnosis (ρ=0.682). No correlation was found between the bacteriology and the presence of pepsin in the airways (ρ=0.006). CONCLUSIONS: The presence of pepsin in the airways shows the occurrence of reflux. The persistence of respiratory symptoms by at least 2 months suggest an endoscopic bronchial examination. This straightforward test confirms the cause possible irritation of the airways and may prevent further diagnostic tests, such as an EGD or pH monitoring esophageal.

SELECTION OF CITATIONS
SEARCH DETAIL
...